The cost of 15 prescription drugs will be lowered following negotiations with the Centers for Medicare and Medicaid Services. Some negotiated costs for the drugs on the list include: - Ozempic, Rybelsus and Wegovy, for Type 2 diabetes, cardiovascular disease and weight loss - $274 negotiated price, down from the $959 - Tradjenta, Type 2 diabetes - $78, down from $488 - Ibrance, breast cancer - $7,871, down from $15,741 - Breo Ellipta, asthma, chronic obstructive pulmonary disease - $67, down from $397. - Vraylar, Bipolar 1 disorder, major depressive disorder, schizophrenia - $770, down from $1,376 The price cuts were negotiated through a program created under the Inflation Reduction Act of 2022. Those price cuts will go into effect in 2026; new prices for the 15 medications will take effect in 2027. The negotiated prices are what Medicare pays drugmakers for the medications and are not necessarily the prices patients will pay out of pocket. However, the new costs will be covered un...